Showing 2451-2460 of 7669 results for "".
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying patients, and offers a no-cost op…
- Enrollment Complete for Journey’s Phase 3 Trials of DFD-29 in Papulopustular Rosaceahttps://practicaldermatology.com/news/enrollment-complete-for-journeys-in-phase-3-trials-of-dfd-29-in-papulopustular-rosacea/2461492/Journey Medical Corporation’s Phase 3 clinical trial program of DFD-29 for papulopustular rosacea is now fully enrolled. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 (Minocycline Modified …
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D array of volumetric thermal zones that delive…
- Beekman 1802 Pledges to Put Nurses First in 2023https://practicaldermatology.com/news/beekman-1802-pledges-to-put-nurses-first-in-2023/2461487/Beekman 1802 is launching "Nurses First," a new program that celebrates nurses in 2023 with surprises, special products, grants, and additional rewards throughout the year. These Kind heroes share the brand's ideology of being Kind to everyone they meet and treat, and always put others before them…
- Acelyrin Inc. to Accelerate Development of Izokibep in HShttps://practicaldermatology.com/news/acelyrin-incs-to-accelerate-development-of-izokibep-in-hs/2461484/Acelyrin Inc’s Izokibep achieved higher orders of Hidradenitis Suppurativa Clinical Responses (HiSCR) in open label Part A of a Phase 2b/3 trial. Izokibep has been administered to over 300 patients, some for up to three years. It is a small therapeutic protein inhibitor of interleukin-17A (IL-17A)…
- Current Depression, Systemic Inflammation Linked in Psoriasishttps://practicaldermatology.com/news/current-depression-systemic-inflammation-linked-in-psoriasis/2461482/Current depression travels with increased neutrophils in psoriasis patients, especially females, finds research in the Journal of Investigative Dermatology. For the study, researchers used data from the U.K. Biobank to look at correlations between current and lifetime depression with neutrophil c…
- Alphyn Biologics' Topical Performs Well in ADhttps://practicaldermatology.com/news/alphyn-biologics-topical-performs-well-in-ad/2461481/Alphyn Biologics’ topical AB-101a met all of its primary endpoints in Phase 2a clinical trial of mild-to-moderate atopic dermatitis (AD). Alphyn plans to present the full results of this trial at a scientific conference and submit a paper for publication in a peer-reviewed journal. The randomize…
- Can Harnessing a Tumor’s Power Help Heal Diabetic Foot Ulcers?https://practicaldermatology.com/news/can-harnessing-a-tumors-power-help-heal-diabetic-foot-ulcers/2461480/Scientists may have found a way to train healthy immune cells to accelerate diabetic wound healing. The findings appear in EMBO Molecular Medicine. Diabetic foot ulcers result in an amputation every 30 seconds on average. One of the fundamental reasons behind the non-healing status of these ulc…
- Aditxt Forms Adimune, Inc.; Appoints Dr. Friedrich Kapp as Chairman and CEOhttps://practicaldermatology.com/news/aditxt-forms-adimune-inc-appoints-dr-friedrich-kapp-as-chairman-and-ceo/2461479/Aditxt, Inc. has formed Adimune, Inc., a U.S.-based subsidiary, and plans to submit a Clinical Trial Application (CTA) for ADI-100, which consists of two DNA molecules that restore immune tolerance in autoimmune disease. The CTA application will request approval for Adimune to conduct the first-i…
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into their veins. Incarcerated men who volun…